Floatz logo

Endostar

Non-small Cell Lung Cancer

Henan Cancer Hospitalprotein_peptidePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
78/ 100
Competitive Position
59/ 100

Competitive context

1205 Active assets in the Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Endostar is also rated in:

colorectal neoplasmDormant
B
Indicative ·
63 / 100
View asset →
Leptomeningeal MetastasisDormant
B
Indicative ·
62 / 100
View asset →
AngiogenesisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →